Tirzepatide
Also sold as Mounjaro, Zepbound
About
About Tirzepatide
A synthetic dual agonist peptide, tirzepatide activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. The compound produces significant improvements in glycemic control and body weight reduction. Primary clinical applications include treatment of type 2 diabetes mellitus and chronic weight management in adults with obesity.
Science
Mechanism of Action
Tirzepatide is a dual GIP/GLP-1 receptor agonist. GLP-1R activation suppresses appetite, stimulates glucose-dependent insulin secretion, slows gastric emptying, and reduces glucagon. GIP receptor activation enhances insulin secretion synergistically, improves adipose tissue lipid metabolism, and may modulate central appetite regulation. The combination produces greater weight loss and metabolic improvement than GLP-1 agonism alone.
Dosing
Typical Protocol
Week 1–4: 2.5 mg subcutaneously once weekly. Week 5–8: 5 mg once weekly. Ongoing titration: increase by 2.5 mg every 4 weeks as tolerated, up to 15 mg/week. Maintenance: 10–15 mg once weekly for maximum efficacy. Contraindications mirror semaglutide: MEN2, medullary thyroid carcinoma, pancreatitis.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This is an FDA-approved finished drug. Now that its FDA-declared shortage has resolved, federal law no longer lets compounding pharmacies make bulk copies of it under Section 503B. Compounding under Section 503A stays possible only for a narrow, individually documented clinical need, such as a verified allergy to an inactive ingredient in the approved product, or a strength or dosage form the manufacturer does not make. Cost savings or convenience are not, by themselves, a lawful basis for compounding it. The FDA-approved product from a licensed pharmacy is the default; a compounded version should carry a clear, patient-specific clinical rationale.
Off the FDA drug shortage list. Verified June 1, 2026 via the openFDA drug shortage database.
FDA declared the shortage resolved on October 2, 2024. Enforcement discretion for compounding ended February 18, 2025 under Section 503A and March 19, 2025 under Section 503B. FDA announcement.
Evidence
Evidence Tier
Supported by the clinical trial data required for FDA approval, representing the highest evidence bar. Safety and efficacy have been established in multiple phases of human clinical trials.
Compare verified providers offering Tirzepatide
All 23 audited providers, ranked by Vial Check by default. Click any column to sort.
Compound comparisons
Compare Tirzepatide
Tirzepatide set against other compounds people weigh it against.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.